# Liver toxicity and veno-occlusive disease on inotuzumab ozogamicin and gemtuzumab ozogamicin: risk reduction, monitoring, hold and stop rules

Source: https://onco.cc/protocols/veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin/  
OnCo record `veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Inotuzumab ozogamicin and gemtuzumab ozogamicin can harm the liver and can block its small blood vessels (veno-occlusive disease), more often when a transplant follows. Liver blood tests are taken around each dose, a dose is delayed if they rise, and the drug is stopped if the blockage occurs. Fast weight gain, a swollen or painful tummy or yellow skin need a call to your team at once.

## Summary

The reader's own unit's policy comes first. Both drugs carry calicheamicin and both US labels carry a boxed warning for hepatotoxicity including veno-occlusive disease (VOD). The figures come from the labels. Inotuzumab ozogamicin, adults (INO-VATE): VOD in 23 of 164 (14%), in 18 of the 79 who went on to a transplant (23%) and in 5 of 164 (3%) with no transplant in between, up to 56 days after the last dose; a median of 15 days after transplant. Children (ITCC-059): 8 of 53 (15%). Gemtuzumab ozogamicin with chemotherapy (ALFA-0701): 6 of 131 (5% in the US label, 4.6% in the EU SmPC), a median of 9 days after a dose (range 2 to 298); the US label counts 3 of the 6 as fatal and the EU SmPC 2.

Before inotuzumab ozogamicin: the EU SmPC contraindicates it after confirmed severe or ongoing VOD and in serious ongoing liver disease, and asks for people with a history of liver disease to be evaluated first; the US label has no contraindication and names the same groups as at increased risk. For people going on to a transplant both labels recommend 2 cycles, and a third may be considered for those without complete remission and MRD negativity after 2. The EU SmPC says conditioning with 2 alkylating agents should be avoided (VOD in 6 of 11 against 9 of 53 with one) and that transplant with bilirubin at or above the upper limit of normal (ULN) needs careful consideration (7 of 12 against 11 of 67); the US label reports both as risk factors without that instruction. A company-funded expert panel (2018) adds early transplant referral and a preventive medicine such as ursodiol for everyone exposed; neither label mentions ursodiol, and of two small retrospective studies (abstracts only) neither found a significant fall in liver toxicity overall, though one found fewer grade 3 AST rises with ursodiol and no fewer cases of VOD.

Monitoring: ALT, AST, total bilirubin and alkaline phosphatase before and after each dose of inotuzumab ozogamicin and before each dose of gemtuzumab ozogamicin, with a watch for rising bilirubin, a large or painful liver, rapid weight gain and ascites. Bilirubin alone may miss cases (both Mylotarg labels, Besponsa EU SmPC).

Hold rules. Inotuzumab ozogamicin (both labels): interrupt when bilirubin is above 1.5 times ULN and AST or ALT above 2.5 times ULN, until both recover, unless due to Gilbert's syndrome or haemolysis; stop for good if they do not recover. An interruption of 7 days or more omits the next dose, 14 days or more cuts the next cycle's total dose by 25%, and beyond 28 days stopping is considered. Gemtuzumab ozogamicin: the US label delays for bilirubin above 2 times ULN or AST or ALT above 2.5 times ULN and omits a dose delayed more than 2 days; the EU SmPC joins the two thresholds with 'and' and says to consider omitting.

If VOD occurs both drugs are stopped (inotuzumab ozogamicin permanently) and the syndrome is treated according to standard medical practice, which the labels do not define: the transplant protocol sets out diagnosis, grading, supportive care and defibrotide after a transplant. No diagnostic criteria read were written for VOD on these drugs without a transplant, and no source read for this page says defibrotide is licensed for it.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: VOD on inotuzumab; SOS on inotuzumab ozogamicin; veno-occlusive disease on Besponsa; veno-occlusive disease on Mylotarg; sinusoidal obstruction syndrome on gemtuzumab ozogamicin; calicheamicin liver toxicity; raised liver enzymes on inotuzumab ozogamicin; inotuzumab cycles before transplant; hepatotoxicity on gemtuzumab ozogamicin

## Connected records

- protocols: [Hepatic dose adjustment of anticancer drugs in reduced liver function](https://onco.cc/protocols/hepatic-dose-adjustment-of-anticancer-drugs/), [Raised liver enzymes on targeted anticancer drugs: monitoring, hold and stop rules](https://onco.cc/protocols/raised-liver-enzymes-on-targeted-anticancer-drugs/), [Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring](https://onco.cc/protocols/hct-conditioning-and-engraftment-care/), [Veno-occlusive disease of the liver (sinusoidal obstruction syndrome) after stem cell transplant: prevention, monitoring, diagnosis and defibrotide](https://onco.cc/protocols/hepatic-veno-occlusive-disease-after-transplant/)
- pairings: [Caution: inotuzumab before transplant (veno-occlusive disease)](https://onco.cc/pairings/inotuzumab-then-transplant-caution/)
- drugs: [Defibrotide](https://onco.cc/drugs/defibrotide/), [Gemtuzumab ozogamicin](https://onco.cc/drugs/gemtuzumab-ozogamicin/), [Inotuzumab ozogamicin](https://onco.cc/drugs/inotuzumab-ozogamicin/)
- technologies: [Allogeneic stem cell transplantation](https://onco.cc/technologies/allogeneic-hsct/)
- terms: [Conditioning regimen (myeloablative, reduced-intensity)](https://onco.cc/terms/conditioning-regimen/), [Dose reduction, interruption and discontinuation](https://onco.cc/terms/dose-modification/), [Hepatotoxicity (liver enzyme elevation)](https://onco.cc/terms/hepatotoxicity/)

---
JSON: https://onco.cc/api/v1/entities/veno-occlusive-disease-on-inotuzumab-and-gemtuzumab-ozogamicin.json